FONT-SIZE Plus   Neg

MMRC And Synta Pharma Begin Ganetespib Clinical Trial In Multiple Myeloma

Synta Pharmaceuticals Corp. (SNTA) and the Multiple Myeloma Research Consortium or MMRC announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals, as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADE) for the treatment of relapsed multiple myeloma.

The trial, made possible by the funding up to $1 million by the Multiple Myeloma Research Foundation (MMRF), will be conducted through the MMRC. The MMRC is a consortium of sixteen world-renowned academic institutions and community centers whose mission is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Apple Inc. plans to launch a new guide for Apple TV during a product event in California today, according to Recode. While major video partners have signed up to be a part of the new Apple TV guide, Netflix Inc. will reportedly not be participating. Wal-Mart Stores Inc. is gearing up for the upcoming holiday season by deploying an army of Holiday Helpers to help customers get through the checkout process faster during the busy period. The retailer has also increased the amount of products available through its Pickup service, lowered the price on thousand of items, and plans to expand the online assortment in the coming months. German automaker Volkswagen Group (VKW.L, VLKAF.PK, VOW.BE), which has been entangled in diesel car emissions cheating issues, returned to profit in its third quarter, on lower special charges and slightly higher sales.
comments powered by Disqus
Follow RTT